V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10468917 | 10042341 | 1.7 | 53.3 | Palliative (P) | 2018-04-17 | 2018-06-01 | CISPLATIN + ETOPOSIDE | 02 | N | CISPLATIN + CAPECITABINE + EPIRUBICIN | 101316497 |
| 10468956 | 10042343 | 1.67 | null | Disease modification (D) | 2018-08-27 | 2018-08-27 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | N | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101651320 |
| 10468967 | 10042344 | 1.68 | 61.8 | 03 | 2018-10-21 | 2018-10-28 | Obinutuzumab + Venetoclax | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 100902118 |
| 10469277 | 10042346 | 1.71 | 69.8 | Palliative (P) | 2019-09-29 | 2019-10-12 | null | 02 | N | CISPLATIN + PEMETREXED | 100900403 |
| 10469283 | 10042347 | null | 87.4 | Curative (C) | 2019-03-05 | 2019-03-16 | BLEOMYCIN | 02 | N | ANAGRELIDE | 101105625 |
| 10469522 | 10042349 | 1.69 | 127 | Neo-adjuvant (N) | 2021-07-26 | 2021-08-10 | null | 02 | null | FLAIR TRIAL | 100190681 |
| 10469587 | 10042351 | 1.8 | 74.8 | Curative (C) | 2017-08-04 | 2017-08-11 | CABOZANTINIB | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 100853661 |
| 10469694 | 10042353 | null | 62.9 | Curative (C) | 2018-06-17 | 2018-06-17 | Fulvestrant + Palbociclib | 02 | null | DASATINIB | 101595280 |
| 10469699 | 10042354 | 1.68 | 78.1 | Curative (C) | 2020-12-04 | 2020-12-04 | FLUOROURACIL + MITOMYCIN + RT | 2 | null | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101325936 |
| 10469752 | 10042355 | 1.67 | 82 | Curative (C) | 2020-12-07 | 2020-12-13 | GEMCITABINE + PACLITAXEL ALBUMIN (ABRAXANE) | 02 | N | CHOP | 100084169 |
| 10469794 | 10042357 | 1.84 | 77.9 | null | 2021-01-23 | 2021-01-27 | LENVATINIB | 02 | null | OSIMERTINIB | 101157420 |
| 10469800 | 10042358 | 1.69 | 110 | 03 | 2019-07-09 | 2019-07-21 | Bortezomib + Daratumumab | null | null | MYELOMA XI TRIAL | 100844177 |
| 10469848 | 10042359 | 1.8 | 91.6 | Palliative (P) | null | 2017-08-19 | BENDAMUSTINE | N | N | AFATINIB | 101176937 |
| 10469937 | 10042360 | 1.67 | 78.2 | Curative (C) | null | 2018-10-30 | Fulvestrant + Palbociclib | 02 | N | CISPLATIN + RT | 101699670 |
| 10470026 | 10042361 | 1.77 | 77.3 | Palliative (P) | 2019-08-08 | 2019-08-08 | MYELOMA XI TRIAL | 02 | N | IDELALISIB + RITUXIMAB | 100238493 |
| 10470192 | 10042364 | null | null | null | null | 2019-02-07 | FEC 60 or 75 | N | N | CISPLATIN + CYTARABINE + RITUXIMAB | 100390822 |
| 10470368 | 10042365 | 1.7 | 82.6 | 03 | 2019-09-03 | 2019-09-10 | Cabazitaxel | 02 | N | RALTITREXED | 101639302 |
| 10470723 | 10042369 | 1.81 | 76.1 | 03 | 2018-11-24 | 2018-11-29 | Nilotinib | 02 | N | NILOTINIB | 101865441 |
| 10470847 | 10042371 | 1.66 | 86.9 | 03 | 2017-07-01 | 2017-07-10 | OSIMERTINIB | 02 | null | SCOPE2 TRIAL | 100737037 |
| 10470868 | 10042372 | 1.72 | 133 | Palliative (P) | 2018-11-21 | 2018-11-28 | Cisplatin + Radiotherapy + CISPLATIN | 02 | N | AFATINIB | 100394845 |
| 10470896 | 10042374 | 1.53 | 86.4 | null | 2020-08-21 | 2020-08-21 | MUK 6 TRIAL | 02 | null | DOXORUBICIN | 101400672 |
| 10470945 | 10042375 | 1.5 | 77 | Palliative (P) | 2021-12-03 | 2021-12-05 | Sorafenib | 02 | null | ANAGRELIDE | 100242037 |
| 10471091 | 10042377 | 1.8 | 69 | Palliative (P) | null | 2021-05-23 | null | 02 | N | CTD | 100897364 |
| 10471302 | 10042381 | 1.66 | 71.15 | Curative (C) | null | 2015-06-26 | Bendamustine +/- Prednisolone | null | N | DOXORUBICIN + IFOSFAMIDE | 101469298 |
| 10471336 | 10042382 | 1.63 | 65.4 | Palliative (P) | null | 2019-10-22 | GEMCITABINE + NAB PACLITAXEL | N | N | ABEMACICLIB | 100291093 |
| 10471432 | 10042384 | 1.8 | 77.5 | Palliative (P) | 2019-07-03 | 2019-07-08 | Brentuximab | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101558510 |
| 10471444 | 10042385 | null | 41.3 | 03 | 2018-02-22 | 2018-03-08 | VINCRISTINE | null | null | CISPLATIN + RT | 100542037 |
| 10471450 | 10042386 | 1.46 | 56.6 | Palliative (P) | null | 2018-02-05 | VINORELBINE | N | N | LETROZOLE + PALBOCICLIB | 101149408 |
| 10471485 | 10042387 | 1.87 | 0 | null | 2022-03-14 | 2022-03-14 | Melphalan IV High dose | 02 | null | BLEOMYCIN | 100395654 |
| 10471549 | 10042388 | 0 | 91 | null | 2016-11-17 | 2016-11-23 | null | N | N | CISPLATIN + DOXORUBICIN + METHOTREXATE | 100835598 |
| 10471964 | 10042394 | 1.6 | 85.3 | null | 2019-10-07 | 2019-10-07 | CETUXIMAB + IRINOTECAN + MDG | 02 | null | CHOP | 100669651 |
| 10472084 | 10042395 | 1.66 | 61.1 | Palliative (P) | 2019-07-23 | 2019-07-23 | Nilotinib | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101054821 |
| 10472185 | 10042396 | 1.58 | 78 | Disease modification (D) | null | 2016-10-21 | CARBOPLATIN + FLUOROURACIL | null | N | LENALIDOMIDE + RITUXIMAB | 101530962 |
| 10472188 | 10042397 | 1.68 | 80.5 | null | 2017-10-21 | 2017-10-28 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN | 101541824 |
| 10472239 | 10042398 | 1.6 | 66 | Neo-adjuvant (N) | 2019-05-17 | 2019-05-22 | null | null | null | CAPECITABINE + STREPTOZOCIN | 101125620 |
| 10472359 | 10042399 | 1.8 | 77.3 | Palliative (P) | 2016-08-12 | 2016-08-12 | OSIMERTINIB | 02 | null | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 100846632 |
| 10472514 | 10042401 | 1.49 | 62.7 | Palliative (P) | 2018-03-08 | 2018-03-21 | ABVD | null | null | CISPLATIN + CYTARABINE + ETOPOSIDE + RITUXIMAB | 101726667 |
| 10472560 | 10042403 | 1.66 | 82.4 | 03 | null | 2017-02-09 | VINORELBINE | 02 | N | PEG INTERFERON | 101304293 |
| 10472609 | 10042404 | 1.56 | 0 | 03 | null | 2021-08-28 | VEPEMB | 01 | null | CARBOPLATIN + LIPOSOMAL DOXORUBICIN | 100886658 |
| 10472643 | 10042405 | 1.58 | 94 | Neo-adjuvant (N) | 2020-03-15 | 2020-03-29 | DOXORUBICIN | 02 | N | PARTNER TRIAL | 100471881 |
| 10472666 | 10042406 | 1.52 | 68 | Curative (C) | 2018-02-06 | 2018-02-17 | ACELARATE Trial | N | N | CYTARABINE + VENETOCLAX | 101025856 |
| 10472673 | 10042407 | 1.71 | 95 | Curative (C) | 2018-08-14 | 2018-08-21 | CARFILZOMIB | 02 | N | CISPLATIN + ETOPOSIDE | 101243986 |
| 10472684 | 10042408 | 1.8 | 77.7 | Curative (C) | 2019-05-07 | 2019-05-08 | ACTICCA-1 Trial | 02 | null | CISPLATIN + PEMETREXED | 100006442 |
| 10472840 | 10042410 | 1.69 | null | Curative (C) | 2018-04-07 | 2018-04-13 | FLUOROURACIL + OXALIPLATIN | 02 | N | CVD | 101513891 |
| 10472849 | 10042411 | 1.65 | 46 | 03 | 2018-01-04 | 2018-01-10 | Cape+Cetuximab+Oxalip (2 wk) Load | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + METHOTREXATE + RITUXIMAB + VINCRISTINE | 100770381 |
| 10472919 | 10042412 | 1.82 | 79 | Curative (C) | 2017-09-29 | 2017-10-11 | AZACITIDINE + VENETOCLAX | 02 | N | GEMCARBO | 100849447 |
| 10473113 | 10042413 | 1.78 | 60.6 | Palliative (P) | 2022-03-18 | 2022-04-09 | Doxorubicin 75mg/m2 | 02 | N | OXALIPLATIN + RALTITREXED | 100329187 |
| 10473122 | 10042414 | 1.6 | 82.4 | Adjuvant (A) | 2019-07-13 | 2019-07-13 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 02 | N | LOMUSTINE + PROCARBAZINE + VINCRISTINE | 101368757 |
| 10473197 | 10042415 | 1.49 | 70.4 | Neo-adjuvant (N) | 2018-07-10 | 2018-07-19 | ANAGRELIDE | 02 | N | ANAGRELIDE | 100911523 |
| 10473222 | 10042416 | null | null | 03 | 2018-06-22 | 2018-07-07 | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 02 | N | GEMCITABINE + PACLITAXEL | 101246382 |